Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers Aug 24, 2020 08:30AM
Aimmune Therapeutics (AIMT) Announces Full Results of its Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA Published in The Lancet Child & Adolescent Health Jul 21, 2020 08:32AM
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health Jul 21, 2020 08:30AM
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers May 28, 2020 07:30AM
Aimmune Therapeutics (AIMT) Submits MAA to EMA for AR101 for Peanut Allergy Jun 28, 2019 07:00AM


Jun 28, 2019 07:00AM Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
Jun 4, 2019 10:01AM Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
Jun 4, 2019 07:06AM Aimmune Therapeutics (AIMT) Says New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
Jun 4, 2019 07:01AM New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
Jun 2, 2019 07:01AM Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
Nov 18, 2018 04:45PM Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine